Ph.D. and M.A., economics, Harvard University; B.A., economics, Miami University
Summary of Experience
Dr. Birnbaum joined Analysis Group in 1997, and has been instrumental in establishing the national prominence of the firm's Health Economics and Outcomes Research practice. An applied microeconomist, Dr. Birnbaum has conducted wide-ranging economic investigations regarding the real-world comparative effectiveness of alternative treatments, the direct and indirect costs of illness, and models regarding the budget impacts and societal costs of various pharmaceutical, device, and medical interventions. He is an expert in the use of public and private payer claims databases, and has used these and other data sources to conduct health economics and outcomes research for pharmaceutical and device manufacturers, managed care organizations, and government agencies. Dr. Birnbaum also has provided expert testimony and litigation support in matters regarding Medicare, Medicaid, and private insurer reimbursement; managed care issues; comparative effectiveness; and allegations of off-label promotion of prescription drugs. He has been a discussant at the Food and Drug Administration regarding post-marketing requirements for prescription opioid products. Dr. Birnbaum serves on the editorial board of PharmacoEconomics and Drugs - Real World Outcomes, and has published articles in many leading medical, health economics, and managed care journals. He is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Institutional Council and co-chair of the 2012 ISPOR research review committee.